SER Stock Forecast & Price Target

Serina Therapeutics is attractive because its POZ platform directly targets a major drug-development pain point: achieving sustained exposure with lower peak-related toxicity, a thesis already supported by prior zero-order delivery data and now reinforced by SER-252’s sustained pharmacokinetic profile in Cohort 1. The blinded 8-patient study, with 6 active and 2 placebo patients, showed clean safety, advancement to Cohort 2, and exploratory motor-function improvement at the lowest of five planned dose levels, while topline SAD data from all 5 cohorts (n=40) remain on track for 1H 2027. Beyond the lead program, Serina has a sizable addressable Parkinson’s market, a 505(b)(2) regulatory path aligned in August 2025, and earlier-stage assets SER-270 and SER-290 that broaden optionality, while revenues currently come from grant revenue.

Serina Therapeutics is a clinical-stage biotech with no approved products, a limited operating history, and a single reportable segment focused on POZ platform R&D, leaving it dependent on grant revenue and external capital while it continues to post significant operating losses. The near-term investment case is highly binary around the upcoming P1b readout for SER-252 in advanced Parkinson’s disease, where unexpected safety signals would be a major negative and even modest efficacy may be insufficient against an increasingly competitive PD landscape. Regulatory and commercialization risks are also elevated after a prior clinical hold, and any eventual approval would still need strong pricing, reimbursement, and adoption versus existing OFF-time therapies such as Onapgo, Duopa, and Vyalev.